Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
April 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 |
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Press releases published on April 27, 2025
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
·
April 27, 2025
NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based …
Precede Biosciences Presents Data at AACR 2025 Demonstrating Ability to Resolve Gene Expression for Thousands of Tumor-Specific Genes from a Simple Blood Test
GlobeNewswire
·
April 27, 2025
Comprehensive epigenomic platform enables systematic and quantitative prediction of tumor gene expression from cell-free DNA Genes include key targets for next generation precision medicines, such as NECTIN4, B7H4, HER3, DLL3, MUC1, MET, and HER2 and …
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
GlobeNewswire
·
April 27, 2025
Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72 HER2-positive cancers represent up to 30 …
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
GlobeNewswire
·
April 27, 2025
REDWOOD CITY, Calif., April 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced new clinical data for …
Mitolyn Reviews: DO NOT Spend A Dime Until You’ve Read This Report?
GlobeNewswire
·
April 27, 2025
Albany, New York, April 27, 2025 (GLOBE NEWSWIRE) -- Various weight loss supplements make exaggerated promotional statements that obscure the real value of actual customer feedback with measurable results. The health and wellness industry welcomes Mitolyn …
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
GlobeNewswire
·
April 27, 2025
STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for …
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
GlobeNewswire
·
April 27, 2025
CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025 …
Best Male Enhancement Pills & Libido Booster For Men: (Penis Enlargement Pills) Over The Counter Best ED Pills Non Prescription – By Performer 8
GlobeNewswire
·
April 27, 2025
Atlantic City, New Jersey, April 27, 2025 (GLOBE NEWSWIRE) -- Best Male Enhancement Pills 2025 Review: More than 50% of men now face erectile dysfunction after the age of 40. In a few cases, men in their 20s and 30s face a similar situation. If you think …
2025 (Spring) Pharmaceutical Machinery Exposition Concludes Successfully
GlobeNewswire
·
April 27, 2025
BEIJING, April 27, 2025 (GLOBE NEWSWIRE) -- On April 25, 2025, the 66th (Spring 2025) National Pharmaceutical Machinery Exposition …